A Phase 2 interventional study of RABI-767 in Acute Pancreatitis, sponsored by Panafina, Inc.. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Panafina, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Pancreatitis with a site in United States — 44 open to participants now, 49 under way, 2 of them phase 3. Pancreatitis · United States.
Among the 139 studies in Pancreatitis with a site in United States, this one is the 65th largest by planned enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2024, is one of 22 in phase 2, reaches primary completion later than 11 of the 48 other live ones, and was the 114th registered.
558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.
Browse Pancreatitis studies →44 of the 139 studies in Pancreatitis with a site in United States are open now. Recruiting first, the newest first:
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+
Anna Evans Phillips · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–80
University of Southern California · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 30 · Phase 3 9 · Phase 4 11
First in 1997; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 100 across 349 interventional studies indexed under Pancreatitis.
Median enrollment 60 across the 97 interventional studies, 433 across the 41 observational. Of the 76 that completed or were terminated, 37 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 139 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Panafina, Inc. as lead sponsor.
Panafina, Inc. has 1 study filed under Pancreatitis — fewer than ten, so there is no comparison to draw.
18 of the studies in Pancreatitis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05252754Phase 3Johns Hopkins UniversityRectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis | 2026-12 |
| NCT06691893Phase 3Massachusetts General HospitalEvaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients | 2027-04-15 |
| NCT07583342Northwell HealthEvaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis | 2026-12 |
| NCT05659147Children's Hospital Medical Center, CincinnatiImaging Biomarkers of Pancreatic Function and Disease | 2026-12 |
| NCT06080789Panafina, Inc.A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 139 studies in Pancreatitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis.
The main question the study aims to answer is:
The study also aims to answer:
Study participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only.
The study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-dose 125 mg RABI-767 plus standard-of-care
Drug: RABI-767
No Intervention, Standard-of-Care Only
125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
Number of Participants with Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the study intervention, regardless of its causal relationship to the study intervention. For the purposes of this study, any AE occurring in any study participant (regardless of treatment group assignment) at any time after enrollment/randomization, even if no study intervention has been administered, will be recorded.
Time frame: Enrollment/Randomization to Day 28 (or hospital discharge, if earlier)
Number of Participants with Serious Adverse Events
A serious adverse event (SAE) is an AE, regardless of causality, that fulfills one or more protocol defined criteria for being serious.
Time frame: Enrollment/Randomization to Day 35 Follow-up
Change from Baseline in Clinical Chemistry Parameters
Time frame: Baseline to Day 7
Change from Baseline in Hematology Parameters
Time frame: Baseline to Day 7
Change from Baseline in Vital Signs
Time frame: Baseline to Day 7
Change from Baseline in Pulse Oximetry and Oxygen Delivery Measurements
Time frame: Baseline to Day 7
Development of Severe Acute Pancreatitis
Defined as \>48 hours persistent organ failure
Time frame: Day 1 to Day 28 (or hospital discharge, if earlier)
Development of New Onset Moderately Severe Acute Pancreatitis
Defined as transient organ failure and/or local or systemic complications without persistent organ failure
Time frame: Day 1 to Day 28 (or hospital discharge, if earlier)
Development of Pancreatic Necrosis
As identified on CECT/CEMRI imaging; may be further sub-grouped into \<30%, 30%-50%, and \>50% pancreatic necrosis, if data allow.
Time frame: Baseline to Day 60 Follow-up
Development of Local Complications of Acute Pancreatitis
As identified on CECT/CEMRI imaging; may be further sub-grouped by type of complication, if data allow.
Time frame: Baseline to Day 60 Follow-up
Mortality due to acute pancreatitis and/or complications secondary to acute pancreatitis
Death caused by acute pancreatitis and/or complications secondary to acute pancreatitis
Time frame: Day 1 to Day 60 Follow-up
Mortality due to any cause
Death due to any cause
Time frame: Day 1 to Day 60 Follow-up
Days in Hospital
Time frame: Day 1 through Day 28 (or hospital discharge, if earlier)
Re-hospitalization for acute pancreatitis or related complications
Number of participants re-hospitalized for acute pancreatitis or related complications out of total participants who are discharged.
Time frame: From initial hospital discharge to Day 35 Follow-up
Length of Stay in Intensive Care Unit
Time frame: Day 1 through Day 28 (or hospital discharge, if earlier)
Development of New Onset Infection
May be further sub-grouped by: pancreatic, peripancreatic, and extra-pancreatic infections, as data allow.
Time frame: Day 1 to Day 28 (or hospital discharge, if earlier)
Change in Modified Marshall Score
Time frame: From Baseline through Day 28 (or hospital discharge, if earlier)
Change in Sequential Organ Failure Assessment (SOFA) Score
Time frame: From Baseline through Day 28 (or hospital discharge, if earlier)
Change in Systemic Inflammatory Response Syndrome (SIRS) Assessment
Time frame: From Baseline through Day 28 (or hospital discharge, if earlier)
Change in Abdominal Pain Numeric Rating Score
Time frame: From Baseline through Day 28 (or hospital discharge, if earlier)
Change in Computed Tomography Severity Index (CTSI) Score for Pancreatitis
Time frame: From Baseline through Day 60 Follow-up
Change in Modified Computed Tomography Severity Index (mCTSI) Score for Pancreatitis
Time frame: From Baseline through Day 60 Follow-up
Not enrolling at this site.
Plan to share: No — There is no plan to make individual participant data (IPD) available to other researchers.
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 22 phase 2 interventional studies under Pancreatitis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 110. This study's planned 30 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.